Abstract: In order to control volatilization or release of organic solvent, especially formaldehyde, and to adsorb them, and at the same time, to improve weather resistance, water resistance, stain resistance and fungus resistance, natural paint is composed of vegetable drying oil, haze wax, candelilla wax and carnauba wax as the main components, and contains at least one or more of rosin, silk powder and component of rice bran.

Abstract: In order to control volatilization or release of organic solvent, especially formaldehyde, and to adsorb them, and at the same time, to improve weather resistance, water resistance, stain resistance and fungus resistance, natural paint is composed of vegetable drying oil, haze wax, candelilla wax and carnauba wax as the main components, and contains at least one or more of rosin, silk powder and component of rice bran.

Abstract: A dual-frequency matching circuit of the present invention comprises an output terminal to which a load is connected, an input terminal through which an input signal is input to the load, a series resonance circuit, which is composed of a series capacitor and a series inductor connected in series to the series capacitor and disposed in such a manner that it is connected in series to the load when observed from the input terminal side, and a parallel resonance circuit, which is composed of a parallel capacitor and a parallel inductor connected in parallel to the parallel capacitor, and disposed in such a manner that it is connected in parallel to the entire portion of the load and the series resonance circuit when observed from the input terminal side.

Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.

Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl: and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity.

Abstract: Thiazolidinecarboxylic acid amides having combined antiallergic and antiasthmatic activities with an antagonist activity against platelet Activating Factor and having the following general formula (I) ##STR1##

Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the homopiperazine part of the molecule with a compound containing the other part of the molecule.

Abstract: A series of new compounds, called "the phomactins" is provided and may be isolated from the culture broth of fungi of the genus Phoma. especially Phomas sp. SANK 11486 (No. FERM BP-2598). These compounds are platelet activating factor antagonists and may be used for the treatment of disorders for which known such agents may also be used.

Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the piperazine or homopiperazine part of the molecular with a compound containing the other part of the molecule.

Abstract: A composition comprising a polymer having dispersed therethrough a prostacyclin derivative selected from the group consisting of compounds of formula (I): ##STR1## (in which R.sup.1 represents hydrogen or lower alkyl, R.sup.2 represents a C.sub.3 -C.sub.12 alkyl group or a C.sub.3 -C.sub.12 alkenyl group; and n is an integer from 1 to 5; and pharmaceutically acceptable salts thereof) can be used to make a medical appliance from which the prostaglandin, having antithrombotic properties, will be released gradually and in a controlled way.

Abstract: A series of new compounds, called "the phomactins" is provided and may be isolated from the culture broth of fungi of the genus Phoma, especially Phoma sp. SANK 11486 (No. FERM BP-2598). These compounds are platelet activating factor antagonists and may be used for the treatment of disorders for which known such agents may also be used.

Abstract: Glycerol derivatives having at least one heterocyclic group on the 1 or 2 position are PAF antagonists which may be used to treat asthma, inflammation and shock.

Abstract: Compounds of formula (I): ##STR1## (wherein n is 0 or 1, R.sup.1 and R.sup.2 are hydrogen or alkyl, one of A.sup.1 and A.sup.2 is --Z--Y and the other is --W--COOH, where W and Z are alkenylene or alkylene and Y is imidazolyl or pyridyl, and the broken lines represent two single bonds or one single bond and one double bond) and their salts, esters and amides have the ability to inhibit the synthesis of thromboxane A.sub.2 and hence are useful in the treatment of prophylaxis of thrombotic conditions. They may be prepared by introducing an imidazolyl or pyridyl group into the corresponding compound in which Y is replaced by an active group or atom.

Abstract: Novel imidazole compounds are disclosed, which are represented by the following general formula: ##STR1## wherein: R.sub.1 represents a cyano group or a --CSNHR.sub.5 group, wherein R.sub.5 represents a hydrogen atom, a C.sub.1-4 alkyl group, or a --COR.sub.6 group, wherein R.sub.6 represents a C.sub.1-4 alkyl group, a halogenated C.sub.1-4 alkyl group, or a phenyl group;R.sub.2 and R.sub.3 each represents a hydrogen atom; a halogen atom; a nitro group; a cyano group; a trimethylsilyl group; a C.sub.3-6 cycloalkyl group; a naphthyl group; a C.sub.1-12 alkyl group which is optionally substituted with one or more halogen atoms, hydroxyl groups, acetoxy groups, C.sub.1-4 alkoxy groups, halogenated C.sub.1-4 alkoxy groups, phenyl groups, halogenated phenyl groups, or C.sub.1-4 alkylated phenyl groups; a C.sub.2-10 alkenyl group which is optionally substituted with one or more halogen atoms; a C.sub.

Abstract: Compounds of formula (I): ##STR1## (in which: R.sup.1 is hydrogen or alkl; R.sup.2 is a variety of groups or atoms; R.sup.3 is optionally substituted hydroxy or --(NH).sub.n --NR.sup.5 R.sup.6, wherein R.sup.5 and R.sup.6 are a variety of groups or atoms, preferably alkyl substituted by heterocyclic, and n is 0 or 1; Q is oxygen or sulfur; and A is a C.sub.1 -C.sub.6 alkylene group) have valuable cardiotionic activity and may be used for the treatment of cardiac disorders. They may be prepared from corresponding compounds containing a benzene ring with a group --QH at the 1-position and a group --CO--CHR.sup.1 --NH--COOR.sup.7 at the 4-position by ring closure and introduction of the group of formula --A--CO--R.sup.3 in any order.

Abstract: Compounds of formula (I): ##STR1## (wherein n is 0, 1 or 2 and R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, X, Y and Z are a variety of groups and atoms) have the ability to inhibit the synthesis of thromboxane A.sub.2 and hence are useful in the treatment or prophylaxis of thrombotic conditions.

Abstract: Compounds of formula (I): ##STR1## (wherein n is 0 or 1, R.sup.1 and R.sup.2 are hydrogen or alkyl, one of A.sup.1 and A.sup.2 is --Z--Y and the other is --W--COOH, where W and Z are alkenylene or alkylene and Y is imidazolyl or pyridyl, and the broken lines represent two single bonds or one single bond and one double bond) and their salts, esters and amides have the ability to inhibit the synthesis of thromboxane A.sub.2 and hence are useful in the treatment or prophylaxis of thrombotic conditions. They may be prepared by introducing an imidazolyl or pyridyl group into the corresponding compound in which Y is replaced by an active group or atom.

Abstract: Prostaglandin derivatives, and specifically derivatives of isocarbacyclin, have an optionally substituted methylene group as a substituent on the .alpha.-carbon atom of the .alpha.-side chain. They have a variety of physiological effects, notably a strong ability to inhibit blood platelet aggregation and a strong anti-ulcer activity.